|
|
By 2009, Reliance Life Sciences (RLS) is planning to launch its first generic drug in international markets. In international market, including US and Europe, the company would compete with global companies such as Mylan or Teva, as well as with the domestic pharma majors like Sun Pharma and Ranbaxy. To have competitive advantage, the company is looking at capital intensive products across all therapeutic segments. However, these drugs are still in the research phase.
Reliance Life Sciences, the newly set up wholly-owned subsidiary of Reliance Pharmaceuticals, will manufacture APIs and generic drugs for the countries across South-East Asia, Africa and CIS as well as for the European and US markets.
|
